Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

regimen

AZCTVENE

Cancer Type
Hematologic, Leukemia - Acute Myeloid (AML)
Intent
Palliative
Regimen Category
evidence-informed
Funding Program
New Drug Funding Program Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia Exceptional Access Program venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia, based on criteria

Regimen Monograph

Aug 2022

Patient Info Sheet

Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.

Last Updated: July 21, 2026